



Demographics and socioeconomic

Total Population (in 1000) (2020)	28,435.94
Population <1 year of age (in 1000) (2020)	410.07
Population 1 year of age (in 1000) (2020)	448.05
Population <5 years of age (in 1000) (2020)	2,363.41
Women of childbearing age (in 1000) (2020)	21,976.40
Infant Mortality Rate (per 1000 live births) (2014)	15.2
Gross national income (US\$ per capita) current value (2020)	0.0
National Health Expenditure Public (2018)	1.7
National Health Expenditure Private (2018)	1.9

Immunization system highlights

- There is no comprehensive multi-year plan (MYP) for immunization.
- There is no information available on the national technical advisory group on immunization. with formal written terms of reference exists.
- No information is available on spending on routine immunization financed using government funds.
- 25% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry implementation is in progress.


Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	2000
Hepatitis B	2000
HPV	
Influenza	2006
MMR1	1998
MMR2	2009
Pentavalent	2004
Pneumococcal Conjugate	2014
Rotavirus	2006
Tdap	
Tetavalent DPT-Hib or DPT-HepB	
Yellow Fever	2000

Immunization Schedule

VEN	Doses					
	1	2	3	4	5	6
BCG	B					
HepB pediatric	B					
DTP-Hib						
DTP-Hib-HepB	M2	M4	M6	M18	Y5	
DTP-Hib-IPV						
DTP-Hib-HepB-IPV						
DTP						
Influenza pediatric						
IPV	M2					
OPV		M4	M6	M18	Y5	
MMR		M18				
Pneumoco conjugate	M2	M4	M12			
Rotavirus	M2	M4				
Td	1st contact					
Tdap						
HPV						

Vaccination Coverage




Surveillance indicators

Acute flaccid paralysis (AFP)	2020
Number of AFP suspected cases	74
AFP rate per 100,000 population <15 years old	0.95
% of cases with 1 adequate samples	53
% of cases investigated within <48 hours	96
% sites reporting	0


Measles-rubella (MR)	2020
Number of MR suspected cases	796
% of cases with adequate investigation	95
% of cases with adequate blood samples	96
% of samples received in laboratory <=5 days	31
% of laboratory samples results <=4 days	11




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Legend
 NB/nb-newborn ● with stockout
 M/m -month ● no stockout
 Y/y-year no data available
 WCBA-women of childbearing age

Vaccine Stockout

VEN	2013	2014	2015	2016	2017	2018	2019	2020
AD syringes						●	●	●
BCG		●	●	●	●	●	●	●
Disposable syringes	●	●	●	●	●	●	●	●
DTP		●		●	●	●	●	●
HepB	●	●	●	●	●	●	●	●
Hib		●		●	●			
Influenza		●	●	●	●	●	●	●
IPV				●	●	●	●	●
Measles		●	●	●	●	●	●	●
Pneumo. conjugate		●	●	●	●	●	●	●
Polio	●	●	●	●	●	●	●	●
Reconst. syringes		●		●	●	●	●	●
Rotavirus		●	●	●	●	●	●	●
Safety boxes	●	●	●	●	●	●	●	●
Tdap								
TT		●	●	●	●	●	●	●
Yellow fever		●	●	●	●	●	●	●